Max Hodak is back.
The co-founder and CEO of Science Corp. joined me for our first-ever live podcast recording, which took place at the Brex headquarters in San Francisco. Thanks so much to all the Core Memory subscribers who turned up.
Max walked us through Science’s technology aimed at restoring vision in the blind, and the company’s new product lines focused on organ transplants and extending the abilities of brains. So, like, totally normal, everyday stuff.
Mostly, we talked about the merger of humans and machines and the progression of bio-tech and AI technology.
We’ve had Max on the show twice now because, for our money, he’s one of the most daring minds in the neuroscience and bio-tech fields, and there’s a decent chance that Science becomes one of the most fascinating companies in the world.
Thanks, of course, to Brex for hosting this event and to you guys for all the great questions.
The Core Memory podcast is on all major platforms and on our YouTube channel over here. If you like the show, please leave a review and tell your friends.
Timestamps
0:00 Intro4:23 One Company or Three? Inside Science's Real Master Plan6:25 Why Is Humanity So Bad at Curing Disease?9:12 Implants That "Work" But Don't: Miracle or Mirage?13:34 Restoring Sight to the Blind: How PRIMA Really Works22:34 The BCI Gold Rush and the Money Problem No One Talks About31:44 Keeping Human Organs Alive Outside the Body36:52 Artificial Wombs and Bodies Grown Without a Brain?41:23 Audience Q&A: Is the AI Biotech Boom Actually Real?47:53 The Bet Every Other Bionic Eye Company Missed56:02 Can a Brain Implant Make Us Superhuman?1:05:04 What Will Surprise Us Most by 2035?
No summary for this episode yet.
Speaker 3
Thanks, everyone, for coming. Thank you, Max, for being here. This is our first ever live in-person podcast event. And huge thanks to all the subscribers and the other people who came. I still appreciate you, maybe slightly less than the subscribers, but still very thankful. Thank you to Brex for hosting us and obviously being such a big sponsor of our show and Thanks to all the people that helped pull us off, including the Core Memory crew back over there. And yeah. Our guest tonight, I think based on the registration list that I saw, lots of you will be familiar with Max Hodak. He's the co-founder and CEO of Science Corporation, which is a fantastic name for a company. and previously was president and co-founder of Neuralink. That's kind of where we got to know each other. Thank you so much for coming.
Speaker 2
Thank you for having me.
Speaker 3
You're our first repeat guest.
Speaker 2
Cool.
Speaker 3
Yeah. It's cool for me. I always enjoy talking to you. I think the first time we met, we Think I was your first official interview back in the early days.
Speaker 2
You guys had never really talked. This was so long ago. I mean, yeah, very. I mean, you'd obviously worked closely with some other people there.
Speaker 3
Yeah, I don't think you guys have done a story. I just remember you telling me how much you hated reporters. It was it was it was was tense for a moment. And now here we are all these years later hanging out. I'm just bad at text. And then the other thing I remember was that you're like, we don't really want to get into the primate trials yet. Let's, you know, we'll get to that eventually. And then there was an event that night that Neuralink had and Elon got up stage and was like, we're putting implants in monkeys. And I remember you cremasing in the back. Yeah. No. Okay. I was going to take a crack at...
explaining science and then I was going to have you tell me sort of how you picture this company. But is, you know, just in the couple of days where I was refreshing myself on everything you guys are doing, you were quiet for a couple of years. And then over the last year, it's just been I feel like one revelation after another for people who don't know. Science has a it's like a product category called Prima where you guys are helping Restore Sight in people who've had degenerative conditions through a sensor that goes in the eye and some glasses. You have this super fascinating technology. It falls into this category called biohybrid, where you're putting neurons in a substrate, a hole in the skull, and then the neurons have synapses that go down and fuse into your brain to give you extra brain power to regenerate things.
a pretty new product line called Vessel, which is around keeping organs alive outside of the body. And then you have a whole set of products, software and hardware that helps other people try to explore brain computer interfaces and associated technology. And so I kind of like watched Each one of these things come out. And then when I was sitting back this morning, I was texting you. I mean, I guess I don't know why I just never pieced everything together before. It just strikes me. You're it seems like you guys are the most ambitious or have the most products aiming for like a general purpose.
augmentation of humans, like a new era of attaching, fixing human beings. Is that how you think about science?
Speaker 2
I mean, so we have a couple different programs, as you mentioned, where the furthest along is our retinal prosthesis to restore vision to the blind, then there's biohybrid as a general purpose brain computer interface technology, which is a little bit earlier, and then our work in perfusion. I mean, our goal is to build a big like an independent medical technology company. There's we don't. At the heart of this, there's really one program. I think this is sometimes seen as like a basket of different projects and it's like they're just kind of duct taped together and why is this one company? Why is this not three companies?
Are there other things that we're doing? Why are we bothering to sell hardware or software to others, to other researchers at all? But really at the heart of this, there's really one idea. So the mission of lowercase s science is to use a differentiated knowledge of the universe to improve the human condition and that's really how I think about our mission at uppercase s science. The video we just watched of looking at these stars, I don't think people realize that if you have sufficient propulsion, you could visit everywhere in the known universe within about 60 years, within one human lifetime.
All of these places are theoretically accessible. But I don't know that the The things that evolved for Earth are going to match that. And so at some point you have to go further. But really right now, we're not working on products imminently that are designed for augmentation. Our goal is to restore function to people that have lost it. And when I think about our roadmap, We're not really thinking about healthy 30-year-olds or healthy 40-year-olds getting our products. Our perspective is that many people, possibly almost everybody, eventually becomes a patient. The human condition is complicated and sometimes it's great and sometimes it's terrible and as you get older it gets trickier.
The Humanity, I think our world view is really oriented around this idea that humanity isn't very good at drug discovery. It's still really mining for oil. And every now and then you find a GLP-1 or just this week there is a major, like there was major progress in pancreatic cancer and every now and then you find these things. very commonly in drug discovery you'll work on a project for a decade and then at the end you'll get a readout and the answer is no and then it's like where do you go from this you can't you can't get an engineering like deep an engineering gradient on that problem and on the contrary neural engineering if we work with the brain directly as a computer this works really well like if you put a cortical motor decoder in a paralyzed patient or an ALS patient An hour later they're playing video games.
Or if you turn on a deep brain stimulator, in 10 seconds a patient goes from not being able to hold a cup of water to being able to write cursive. Or with a retinal prosthesis, which stimulates the cells just past the rods and cones. tens of billions of dollars and many decades of work trying to find drugs to stop the degeneration of the retina, or much less restore vision, using drugs to really no avail. There's been very, very minimal progress. And with our electrical stimulator that, again, just treats the brain basically as a computer, We can take patients from being unable to recognize faces for over a decade to one of our one of our patients in Europe just finished a 300 page novel.
And so humanity is just it like the brain is just more amenable to this type of engineering and it is simultaneously the central object of medicine. Like when you get a vaccine or you check your cholesterol at the end of the day, the thing that you are really So what we're trying to preserve is that the brain activity continues and is interesting. Like you can get a heart transplant or a liver transplant, but you cannot even in concept get a brain transplant. And when you deal with the brain directly, you get these effect sizes that you just don't really see in medicine. And I think it's a broad mandate to develop devices kind of in that world view that restore significant functionality to patients that are in trouble, whether that's because they've, so when you think about like our perfusion platform, initially we're looking at applications around transplantation and there's some really cool research there, but it's really a platform that you can imagine using, like this takes you on a path towards things like total artificial hearts or improving dialysis to something that a patient could live with for decades.
The bio-hybrid is similarly a platform. Initially, we're looking at things like stroke, but there's a range of, there's some really cool research going on that unifies really deeply with what's coming out of the artificial intelligence community, where I think we're kind of rapidly gaining this really cool knowledge of how do brains work and how to engineer them to restore lost functionality that we just could not have talked about five years ago.
Speaker 3
Okay, follow-up questions. I forgot. There will be a Q&A portion of this in about... like 30 minutes. I just wanted to time check myself. So just anyway, start forming your questions. OK, so kind of along the lines of what you're talking about, I spent the last few years covering you guys, covering Neuralink, covering Onward, which makes a spinal implant to help people move again, all of these companies. And I have the similar experience every time, just about, which is I go to Switzerland, I see someone with a spinal implant walk. You know, they were completely paralyzed for 12 years and now they're taking steps across this room and you're like, this is miraculous.
And then it sinks in for a second. It's like, oh, they're not walking at all like they used to. It's fantastic that they can exercise, stand up. It changes their lives in some ways, but then it also doesn't at all. And when I talk to people in these fields, sometimes it's really unclear to me If it's just early days with this technology and like so many things we're used to around Moore's Law, it's going to get better and better and better. Or if this is a different category and it's just we're quite gated. And I didn't know if Prima was like a good place to talk about in relation to this about what's possible with the implant today and then where you think it's going or it seemed like you had broad thoughts already.
Yeah, I mean, it's, I would say broadly, these fields are not like Moore's Law.
Speaker 2
And although Prima might actually be an exception to this, that really is a thing where the electrodes get smaller, the implant gets bigger, there's, you can cover more of the atrophy. That's an area where really we can't think of it more that way. But I'd say broadly, a lot of this stuff, like you're right, like there's the spinal cord injury patients that have BCIs right now, like they're not walking, they're not running, they're not like swimming in pools. This seems very incremental, but that's the way that a lot of this progress in medicine is. It's not these big flashy, it's not like suddenly there's like the problem is solved.
Over the last 20 years for many cancers, survival has doubled, but each of the results looked very incremental. But it's that kind of compounding incremental progress where each time you learn a little bit more and the And to some degree there's a divergence between what's possible in the animal models and what you can do in patients, just because the feedback cycle of human subjects research is so slow. Like if you have to freeze your design for multiple years to put something in a patient, then it really limits the rate at which you can learn things separate from what's possible with the technology.
When you, BCI aside, when I look at broader medicine, one of the areas that I'm most excited about these days is N of 1. like you the conventional approach to drug discovery is you're looking for a thing that you can prescribe to many patients and for like some broad indication the more patients the better that makes it more venture fundable but then you're averaging over the natural variability and complexity of these diseases and biology just often doesn't really work that way but if you have one patient and you have the full toolbox of modern science and you can think you can think about them you can reason about that one case as a really deterministic like biochemical system What's possible is looks totally different than what people think is possible in medicine.
And so there's to some degree divergence between what's possible scientifically, scientifically and technologically, and what is entering practice because of that, that translational gap. And that that I don't know that there's really easy answers. I think for us, we and our our thought one of our thoughts on this is that I think medicine is often too concerned with statistical significance and not concerned enough with the fact size if you If your effect size is small, then it will be tough to translate, and then you'll get into arguments with payers, and then patients will be thinking, do I really want the surgery?
But again, if you can take a patient who can't recognize faces and allow them to read novels, it's like everything is downhill from there. It can still be slow, but those results are still very meaningful, and you can really see how they compound to places that people couldn't imagine. Well, I mean, can we focus on Prima for a second just to go through that?
Speaker 3
So, okay, so you've got a chip today that...
Speaker 2
Yeah, so let me get a little bit of background on Prima. So these are, we're looking at diseases where the, let me back up a second. So in the eye, the eye is, you can think of it almost like a camera. It's not quite a camera in the way that the brain works with it, but like Shines in through an optic that forms an image on the back of the eye. In the back of the eye in the retina, there's really three layers of cells that, I mean, it's more complicated than this, but you can think of it as having three layers of cells. The image hits the rods and cones. These are the kind of conventional light sensitive cells, as many people have heard of.
Rods and cones turn the light into, they release chemicals that then connect to a layer of cells called bipolar cells, bipolar because they've got two ends, and those connect to the retinal ganglion cells, which are the optic nerve. So if the rods and cones have died, the optic nerve might still be there and the bipolar cells might still be there, but the eye is no longer light sensitive. There's a bunch of different families of diseases that cause this macular degeneration. The most common form is age-related macular degeneration. It's One of the most common forms of blindness, retinitis pigmentosa, diabetic retinopathy Starrgart's disease.
There's a bunch of ways that the rods and cones can die. Historically, people have been trying to understand molecularly what's going wrong in these cells and how can we develop a drug that will stop whatever's going wrong in the rods and cones from happening, or even maybe they haven't totally died but they've gone dormant, maybe we can reactivate them. Those drugs broadly haven't had big effects. There's a gene therapy that So in some cases, in some patients, there's a mutation in a gene called RPE65. When that goes wrong, the rods and cones start dying off. There's a gene therapy a while ago that would fix RPE65.
This was acquired for $5 billion by a big drug company. Now that, I mean, it very marginally slows the rate of degeneration. It has some impact, a small impact for some patients, but definitely is not restoring the loss site. In macular degeneration, there's drugs called complement inhibitors that will slow the rate of degeneration by 15 to 20%, but you're still going blind and it's definitely not restoring any vision. The neural engineering view of the world is I don't really care why the rods and cones have died. I don't need to understand molecularly what exactly is going wrong and I don't need to care the difference between retinitis pigmentosa and macular degeneration to some degree.
What I need to do is get a signal back into this cable and If I can do it in the bipolar cells, then that's like that. It was an empirical discovery of our clinical trial that if you activate the bipolar cells, you'll get an image in the mind's eye. They'll see things. There have been lots of research before trying to stimulate the optic nerve directly where they didn't see things. They just got these diffuse flashes of light. Those didn't really add up to vision. The brain doesn't really kind of bind them together into a coherent image. We call these phosphenes. You'll see these artistic representations of maybe the outline of a face with these flashes of light.
But you seeing that through your photoreceptors is very different And so you've done this 100 to 1 compression. And when you stimulate that 100 million channel signal into the 1 million optic nerve cells, you just don't get an image. You kind of get trash. and the bipolar cells are somewhere in between and so there is a discovery. We have figured out how to stimulate the bipolar cells in order to get that coherent form vision image in the mind's eye. Now Prima in its current form, so it's a two millimeter by two millimeter chip that has electrodes that are 0.1 millimeters in diameter. and that is able to get that image.
But it's small. It's like looking through a straw. It's implanted under the retina. It's a one-hour outpatient procedure coming through the front of the eye, leave it under the retina. The cytosurgery is done all the time. It takes a little while to get used to looking at the videos of this, but you can adapt to it. It can be done under local anesthesia. And this is not the final form of this product. We need to make the electrodes smaller. We need to make the implant bigger, cover more of the area of atrophy. We need to potentially individualize it to patients. But it is, I think, a very powerful existence proof that success is possible, that when you do this, you can get a restored image in the mind's eye.
Speaker 3
And success today looks like Dr. Justin Marchegiani I couldn't read a book at all. And now I'm making out letters, I'm making out entire words. I mean, you talked about somebody who read what, like a 300 page novel.
Speaker 2
Dr. Justin Marchegiani Yeah, yeah. Dr. Justin Marchegiani So we're not, we don't, we're not approved yet. So all I can talk about is kind of what happened in the clinical trial. I can't say that it would be like it would do anything particular for some other patient, but the We in the clinical trial you're able to take patients that really had like if you do that the eye chart that you're used to at the letters normally this is put four meters in front in front of you and then you read off as much as you can for these patients they would put it one meter in front of the patient and the patients in our trial they could read a little bit of the first row the very biggest letters with their remaining peripheral vision they're not in total darkness but the whole central Area of High Resolution Color Vision.
Many people don't necessarily know this, but only the central six or seven degrees of your visual field is high resolution color vision. The rest is low resolution, more black and white. But your eyes are constantly darting around several times a second. Your brain is constantly trying to figure out where, if I glance, is that going to best update my uncertainty about the scene? And when I said the eye isn't exactly like a camera, you don't What you perceive is not the image that falls on the retina. First of all, the rods and cones are actually in the back of the retina. It's backwards for boring evolutionary reasons.
But if you were to get that, you'd see like shadows of blood vessels. There'd be all this other stuff including it. But what you actually experience is the world model constructed by the brain. And this world model is this highly semantic, like, Model of Reality. This makes it so that when you look at something, you can kind of intuitively get a sense like, is it hard? Is it going to be cold if I touch it? Is it soft? When you look at a person, you have a mental model of them. And of course, when you're talking to somebody, you're not experiencing them directly. You're experiencing your simulation of them.
And so it's about updating this world model through the cable of the optic nerve. And so the patients, they've lost that high acuity central Co-Color Vision, they have some residual peripheral vision, so they can, many of these patients can walk around, they won't necessarily walk into walls, but they've lost the ability to read, they can't recognize faces, definitely can't drive, and what we can do is restore a patch from that central vision, just that central area of, right now it's black and white, of black and white high acuity vision. And so they it's not individual letters. It's it's a couple letters at a time typically that they can then string together into words.
So they have to kind of look at it in parts. But it's a image just like you you see. And you you think this gets unlike some of the other things that we might have been
Speaker 3
talking about. You think this gets better because you just make the sensor bigger, better, cover more area, denser over time.
Speaker 2
Yeah, well, I mean, if you think about it, the goal is you've got a couple you've got millions of retinal bipolar cells. And if we can selectively stimulate those, then that's all vision is for the brain. And we and so the those cells are The electrode is 100 microns. Every time we stimulate, we drive dozens of them, maybe hundreds. And so that's why it's black and white right now, because color is rolled out. There are different bipolar cells that encode different colors. And so when we stimulate these in bulk, that gets averaged together to white. If you think about it, there's no such thing as a white photon. There's no white laser. when you see white this is a loss of resolving power this is you're getting different like if your vision was infinitely fast you always see flashes of um of of different spectral colors but when we average together red green and blue then you get white and so it's seen as high contrast black and white right now as the electric gets smaller and we're able to stimulate fewer cells at a time we expect to start getting uh color percepts so okay if we look at the
Speaker 3
BCI field more broadly, things that people would maybe be the most familiar with, Neuralink, putting an implant in the motor cortex to help with movement, other people trying to, people doing similar thing for movement, Synchron, Precision Neuroscience, other companies at various stages maybe trying to help with speech, these different functions. Going back to what I was talking about before, I mean, it always feels like there's this limitation because You have to pick a region of the brain. You can only go so deep. Even if you're on the more extreme end like Neuralink and you're doing a surgery, you're still only going millimeters into the brain. So like we've been in this the last eight or nine years have been sort of this gold rush of these BCI companies. You know, this used to be an academic field. Now there's startups galore, many of them very well funded. Do you Unlike Prima, where you kind of see this path ahead, do you think like all of those companies are fundamentally limited in how far they can go?
Speaker 2
I mean, I don't like BCI is not a product. I think people compare us to other BCI companies like all the time, but I think this is and every now and then you'll talk to VCs and a fund will say something like, oh, we have a BCI bet, we're not going to invest in this other one. This is the wrong way to think about it. BCI is a category in the same way that pharma is a category. It's not that VCs will have a BCI bet, it's that there will be BCI specialist funds that do lots of different things. It's really just this alternative approach to these big effects in healthcare. It's different from drugs.
And so in the same way, it's like imagine if like 50 years ago, it's like, oh, like the venture firm is like, oh, no, I've got a drug company. fund more drug companies. There's a huge long list of indications that these things can be helpful for, but we're at the early days of it. I mean, there's some really amazing results from UCSF that deep brain stimulation can be incredibly effective for end stage depression. And now those results come from patients that are considered So, they're suicide risks, so end of life that it justifies these surgeries, but as these devices get smaller and the surgeries get easier and the effects get more specific, like Parkinson's, depression, addiction, epilepsy, And when we looked around at the beginning of, in 2021, at the beginning of science, we asked ourselves, like, what is the most valuable unmet need that could be addressed with BCI-type technology?
We, it was kind of a So that's why it's important to us that the answer is restore vision to the blind. And if you want to do that, there's a couple different places in the brain you can look at doing it. You can look at the retina. The retina connect, the first stop of the retina in the brain is a structure in the thalamus. Or then from there, you can go up to visual cortex. And for a bunch of reasons, we thought that the right place to intervene was in the retina. But there's a lot of detail in this. I mean, this is medicine. This doesn't work for patients that have lost the optic nerve, which is glaucoma.
But for hundreds of thousands, for millions of patients, this comes with the potential of a really significant impact.
Speaker 3
Okay. So in that case, you're talking about millions of people. When I look at some of the other BCI companies, and I get what you're saying. I mean, there's going to be different treatments for different things. There does seem to be a problem, at least from where I sit as a reporter, which is that a lot of these companies, this is a field that moved from academia to full-on Silicon Valley tech startup world, and they've raised tens of millions of dollars, in some cases hundreds of millions of dollars, and then when I start talking to them about who's going to use a spinal implant, who's going to use an implant that's in the motor cortex, you're talking about relatively small populations of people whether you're paralyzed or ALS something like that but you've been funded almost like a consumer technology company or you've at least been funded really your technology would have to become like an elective general purpose type thing like do you agree with my perception and are we on the verge of a whole bunch of these companies It just strikes me there's not going to be enough money from just medical use to
Speaker 2
get past this case. I don't know. It's tough to say that, again, I think this is different than, I mean, we're not working on a motor prosthesis. One of the reasons for that is I think it'll be widely available. I think there'll be many companies that are able to produce motor prostheses and there'll be lots of options for patients to choose from. One of one of the challenges like one of the things I think you're getting at is it's very expensive to develop these technologies right now it costs hundreds of millions of dollars nobody's ever gone from a blank page to putting a brain implant in a patient for a new indication for less than less than about 70 million dollars really more like 100 million dollars in most cases and as long as it is that expensive to develop then you have to charge a lot to have it.
And then you get in. Then there's questions like, right, who's going to pay for it? Is it are there enough patients for that to be worthwhile? So I think it is very important that the cost to develop these things comes down. Now, this is. I have a whole like like health care catastrophe theory of everything here, which is I mean, like 20 years ago, we made we bought far fewer TVs and laptops and phones. Each one was much more expensive. Now we we they're cheaper. We spend many times more total. This is a good thing. Like the investors can look at this. They can be like, cool. Phones, seven percent category market can invest in that, going to get good returns.
There's much more money spent on it total. This is a technological growth industry and everybody's happy in health care. Healthcare Reimbursement Dollars are more or less a fixed bucket of money. It grows at about the rate of tax receipts. And so the problem that we're running into is that people are living longer and there's more products that are able to provide value to patients. And so as patients live longer and there's more stuff that they can buy to get a high quality of life, There's just more stuff to spend money on. And when we spend 10 times as much on laptops, this is great. If we spend 10 times as much on health care, this would be a catastrophe.
And the only way out of this is to bring down the cost of development so that you can charge human scale prices for this. Like I want nothing more than the ability to sell one of our retinal prostheses for like $5,000. It's not going to be $5,000. How much is it? I don't know yet, but it'll be more than that in the beginning because we'll have spent hundreds of millions of dollars to develop it. We've raised about half a billion dollars so far. A lot of that goes towards the retinal prosthesis. There's a bunch of different reasons for this. But I think one of the things that you have to be mindful of also is that when you look This is now a globally competitive industry, and some of the other countries out there are able to do these things a lot more cheaply.
In fact, there's now a company that has a commercial marketing approval for an implantable BCI. It's the first ever, as far as I know, there in China. They did not spend hundreds of millions of dollars to develop this. And one of the correlators of that is that they don't need to charge hundreds of thousands of dollars to each patient. And so I think finding ways to develop these in capital efficient ways is going to be essential at realizing the potential of these different applications. Because when you look at these other companies, it's not that I think that what they're doing is not worthwhile or that there's not a market for it.
It's just a question of, does the venture math work at the scale that it takes to develop these things? So one of the It's not really a product line, but one of the things that we do is we license our electronic stack and we own a foundry and we work with other BCI companies to enable them to become capital efficient. So far all that we've seen are these high We have highly funded, vertically integrated companies that are spending huge amounts of money to develop these things from scratch. But the reality is that a lot of it is the same. Like if you're building a corticomotor decoder or you're building a retinal prosthesis or a cochlear implant or a spinal stimulator, a lot of the electronics are the same and a lot of the fab processes are the same.
And our goal with our ecosystem program which we've actually done a handful of these now a couple have been announced there's more in the works is to make it so that the smaller companies can raise five to ten million dollars and get into humans and prove out in human subjects and you like effect in a clinical indication without having to raise fifty to seventy five million dollars up front to like rebuild all this make all their own chips human rate all their own software make all their own electronics I mean I think that will have a big impact for I'm getting more of these things to more patients because there really is a there's a very long I mean almost anything in medicine ultimately you can rephrase in terms of an impact on the brain Gosh this is going quick I have all these questions I want to ask you but I have to turn it over to you guys in about 10 minutes I think okay let's get weird for a second your this perfusion light vessel that you guys
Speaker 3
have I looked at it kind of quickly over the last day because I didn't even know you guys were already doing this. But so you've kind of made better versions of devices that get used in a hospital to keep organs going outside of the body. That was kind of like my first take. You guys do have like a consumer tech flair to your design on some of these products. Okay, I'm going to get really weird with the next question, but first of all, why are you getting into this? What's the goal of making these products?
Speaker 2
So I think when you think about the BCI field, there's a couple different memes out there of the motivation for these things. I'd say there's a couple frontier BCI labs, and then there's a bunch of medical device companies. Like one of the dominant memes on the Frontier BCI Lab side is that this is about kind of merging with AI and that this is a response to the advances in artificial intelligence. And I do think that there's something to that. And I think that that is a thing on a slightly longer time scale. I think of science really as a longevity company. I think that our real competitors are more like places like Altos Labs or Calico.
And so when I think about the human condition, how can we improve this? We have this very strong existence proof in perfusion technology that miracles are possible. So I first got clued into the opportunity and need here about a decade ago when I read an article in the Lancet, which is a major medical journal, which was a case study of a 17-year-old living in Boston who was waiting for a lung transplant. And while he was waiting for a lung transplant, he was being kept alive on this perfusion circuit that was kind of replacing his lungs into some lesser degree his heart. and after he'd been on this so he so he's in an ice ICU suite he's playing video games doing homework hanging out with friends but is totally dependent on this provision circuit that's keeping him alive and after a while on the transplant list waiting for new lungs he was diagnosed with a complication that made him no longer a priority recipient for new lungs and so they took him off the transplant list in this this Lancet article was about the ethical dilemmas of like what do we do with them because on the one hand you've got this 17 year old who's doing homework and if you turn off the perfusion circuit you will immediately die on the other hand he's it's half a million dollars a month and this is like if this like there were these aggravating quotes in this article from the doctors saying things like this raises fairness issues about if it's fair to leave hit this patient on ECMO as a destination why don't we do this for every patient in cardiopulmonary distress and how his family and friends quote derived benefits from his continued survival and so we have to like reason about this this was just like I didn't really understand what the limitations were needed to learn more about that and so it's a thing we've done over the last few years but clearly there's this existence proof that these these life support systems are capable of miracles that most people don't appreciate and it's the same as And simultaneously, the same type of technology has revolutionized organ transplantation.
20 years ago, if you needed a new kidney, you were on a one-hour tether to the hospital at all times. If the car crash happened at 3 in the morning or surgery happened at 4 in the morning, now it gets scheduled for the afternoon or the next day with a Rested Surgical Team. In many cases, these organs are coming from patients who are quite sick, which is how it became a donor organ in the first place. And just being on this perfusion circuit out of the disease state kind of brings them back to health a little bit. And there's really exciting research going on where if you could keep these organs for longer, for maybe a couple weeks, then you could intervene on them maybe with a gene therapy, ex vivo, where you're not exposing a patient to it, just that organ.
You could even immune match it to a patient. and we and this is all this is all kind of done but it's not there's there are limits the technology that did not feel very fundamental that we really felt like we got a good handle on on where the opportunities and pitfalls were and the and we thought thought could be improved and so I think beyond organ transplantation and other things we're thinking about are like pediatric like Like if you're a three-year-old that needs a heart, you're pretty screwed because a four-year-old heart or two-year-old heart won't fit. And there's not a lot of two-year-old to four-year-old heart donors anyway.
But if you could build a system that they could live with like as a backpack for a decade until they're eligible or 15 years until they're eligible for an adult heart or maybe forever then that just totally transforms how you think about these diseases and this I think is actually like it's really not that crazy I mean there's we we know that a lot that the fundamental medicine there is is potentially possible there's a lot of a lot of problems to solve and we got to a point where we had the conviction to bet real money that we could solve them so okay I think a few months ago I wrote a story on
Speaker 3
a company called Becoming They're making a placenta that they can keep alive via a perfusion system in their lab. It's sort of heading towards becoming an artificial womb, more or less. We just did a video and a story on a company called Bexorg. They use a perfusion system to keep a brain, a human brain, alive outside of the body for up to weeks, I think they can do. Over the last Couple of weeks, there's a story that broke about a company called R3. They're knocking out genes. They're basically growing sacks of organs, or want to, that you could harvest and use for some of these cases that you're talking about. When I write these stories, There's a group of people who are excited and think it's cool, and then there's another group of people who find all this sort of off-putting. How do you think the public? It feels to me like we're on the cusp of some quite dramatic changes with this technology, and I'm curious how people will react to this.
Speaker 2
Yeah, I mean, look, I think that if your child needs a heart transplant and there's nothing available. And so like in the case of that 17 year old, what they did is they there's a there's a filter in the oxygenator in the circuit that needs to be changed every few days because it's this gas exchange membrane that clots. So as the blood flows over it. And so the parents and the doctors didn't want to, they didn't want to unplug this or be like, come into the room. They're like, cool, we're going to turn you off now. So what they did is they stopped changing the filter and the oxygenator. And a couple of days later, the kid died.
And I don't think that there's any parent who in that situation is going to be like, no, I don't want the artificial heart system. And this is like this is very serious medicine. I think that people don't want to lose their humanity. And I think it's important that the future is is of humans and for humans and that we preserve these values and we're not producing something totally different. But I think this is like this is very serious medicine and there's At the same time, it opens up, as you mentioned, new possibilities that weren't feasible before. I think you'll see groups work on things like artificial wombs.
Speaker 3
Check out Core Memory later this week. We're going to have some stories on some more of this stuff, but I now know of a handful of companies that are working on growing organs. Essentially, it's like a headless I mean, do you think this will happen in the next 10 years?
Speaker 2
I mean, probably. I mean, that's like probably possible. I mean, we're not growing headless people. I think that's like probably technically feasible. This stuff, it I feel so first of all it's important to remember that everything we do is in dialogue with society you need to get you need to bring people on you have to explain why you're doing it why it's important you have to also there's there's places that they don't want you to go and you have to be open to that but the I think we're where I am and I we're biology is this alien nanotechnology it is this like we were given it by our evolutionary history we have to deal with it but we're we don't really understand it we're not really good at engineering it it does all kinds of crazy stuff and the and there might be ways to simplify some of these problems.
And so I think that for us, like the perfusion circuit approach is probably like better than growing replacement organs and also is a little bit less creepy. But I don't know that the creepiness is going to I think if you can show real impact on patients and I think that when people's feelings change about this when they have a serious diagnosis or a loved one of theirs has a serious diagnosis and they go from thinking like oh I would never put a chip in my brain to being like oh I can talk to my husband again and it gets and at the same time there's there are people out there because it's like it's Free World like people can do what they want saying kind of very speculative things and that doesn't always help but it is important to remember these are like serious surgeries for serious diseases for um with the potential to really help people uh okay I'll do one or two more questions um do we have microphones over to wait oh in
Speaker 3
the audience Okay, Herman's going to help us out. If you guys have a question, put up your hands. I'll just do like a rapid fire one since I see people already have questions. I get bombarded these days with startups who it's like AI meets bio. We've run our model. We're discovering new proteins, new virus, you know, and it's like new medicines. There's so many that I It's impossible for me to tell what's real, what's not. Is this actually happening? Is this not? I always enjoy talking to you because you're well-versed on AI and biotech. If you're sitting where I am, I'm being told The revolution is happening right now, and AI is having its biggest breakthroughs possibly in biotech, and we are on the cusp of discovering all kinds of new medicines and therapies very quickly. Yeah, and I have trouble gauging how excited to actually be about this or not.
Speaker 2
Yeah. I mean, look, I think that a lot of it is real, not all of it. And I think that it will be some of it will come down to our ability to actually run these experiments in humans, because until you've done that, you don't really know. The laboratory mouse is an essential part of the process, but kind of everything works in mice. And so if you've done it in mice, that doesn't really prove anything. And if you've just done it on a computer, that also isn't enough. And the step from going from a computer model to trying something in a human subject is enormous. And so that is going to take time. There's tons of blog posts being like we found all these drugs it's like a small percentage of those are actually going to go to the clinic and and even find out but I think that the progress is coming from AI is largely real and the serious groups that have the resources and capabilities to bring these things through probably I think will get some major results and there's yeah I mean I think it it's tough to give a really generic answer because there's such a broad range because there's just so much out there and there's new things every day. But I think that a lot of it is real.
Speaker 3
Okay. Okay. Okay. I see. Well, where's the microphone? There we go. Okay. Thank you.
Speaker 4
Hi, Max. Yeah. So I'm curious, like my question broadly is like, how do we make sure that neurotech does not end up like pharma? Because like pharma has like a huge lobby and I would argue that like it's not, it doesn't really like think about the patient first anymore. and so like we're kind of on the precipice of all this technology coming into public view and all these players are entering the scene but like we're navigating capitalism and like every like obviously these things need to make money and like you mentioned we need to bring down the cost of development but like how do we steer I guess the development of this young industry away from like what we've seen happen I guess what so how do we make sure that neurotech doesn't end up like
Speaker 2
pharma and I think that the central going back to things earlier like the problem with drug discovery is that the if it's just you don't get these big effect sizes and a lot of it is downstream of that there certainly are I think that your perception that to some degree some of these groups have gotten good at separating financial return from helping people is true. I don't think that that's certainly not the mindset of like scientists and pharma. I think that pharma in general is somewhat unfairly maligned I think that they really are trying to find they want nothing more than to find great drugs that have huge effect sizes and they can like get paid for and help a lot of people um like when you have that that that's the most valuable thing like this idea they're holding back a cure for cancer because then it's not like you're not getting more sick people this is just not the case the problem is that humanity this is just beyond humanity's capabilities and um So healthcare is different than many other industries.
Like 20 years ago we didn't have big autonomous car companies because just like clearly it wasn't there. But we did have drug companies because humans don't like dying and they don't want to be sick and they want to have these things. And so it is a little bit different than many other areas of technology where any given moment in time for kind of the most resources that we can allocate to it will kind of take whatever we can get. and in the case of drug discovery it's just like limited and I think the way that neurotech is different than that is well that will it will be different or not to the degree that we're able to actually get those results and so I would say I'd keep the focus on like what is this the effect size that you're able to see what to what degree can we bring down the costs of development and the Some of these constraints are self-imposed.
There are real regulatory costs. People talk about, oh, it costs like $100 million or more to run a clinical trial. The direct costs of a clinical trial are actually not that high. The real problem is that they take so long to run. And while they're running, you're carrying the costs of this big company. And so just the duration of waiting for this is super expensive. Anything we can do to accelerate regulatory reviews or if we can delegate authority to local IRBs like many other countries do, or like with the FDA, the FDA is small. There's not that many reviewers there for any given area. And so when you look at what Europe does, where Europe has a system of notified bodies, where there's these businesses that are basically blessed by a government to review products, they can have thousands of reviewers in an area.
And so you can get much faster feedback, and you can work much more closely with them. Those are the types of things that I think will allow us to really get the iteration cycles, that allow us to learn, that allow us to make really compelling products. But I'd say pharma is not evil. They just are limited by, like, biology is hard, and humans want whatever we can get, and that is the result of that.
Speaker 3
Let's do one more on that side, and then we'll switch sides. Yeah, sorry. I saw your hand first. Whoops. Sorry. One second. Got to get it for the podcast. Yeah, to this gentleman. Thank you.
Speaker 4
Great. Thank you for the talk. This is great insights. In terms of with regards to Prima, what are some of the fundamental discoveries that you found that others have missed? And then how are you extending those learnings to some of the new products you're developing?
Speaker 2
Why did other people not do this? I mean, this is always like a little bit confusing to me. So there are some, there have been some genuine technical advances. So for example, So when you put an implant in the body, you have to realize there are no truly passive surfaces anywhere in the body. Even bone is constantly getting remodeled. It's all very dynamic. And so when you put a device, it starts getting attacked. And you want to keep your electronics functioning and the metals in there from leaking out. And you want to keep the body from leaking in. We call this packaging and packaging is like a weirdly hard problem.
This is like one of the things that people don't really think about but when you like these these implants often degrade and so the way that people have dealt with this historically like if you think about like a pacemaker the thing that you actually see is like a welded titanium box. because welded titanium does fine in this environment. But if you put in a tiny little film of electrodes, this is going to break down. And so there's a material, silicon carbide, that is a pain in the ass to work with, but we're now getting experience with. You can use it as an outer encapsulating layer, and this will outlast the patient.
And so there's a handful of results, things like that, that are really pushing the field forward. Now there's I'd say that the central thing that made Prima more effective than the prior devices was the subretinal placement so there have been a lot of groups that have tried to simulate the optic nerve so when you think about the retina the light turns in from the front the first layer of cells light hits is are the optic nerve cells past that or the bipolars past that or the rods and cones and so if you just like put an electrode array in the eye and you just lay it on the retina What you're getting are those 1 million optic nerve cells.
And it's the easiest. It's like the place to be. You don't risk a retinal detachment so much by putting it there. It's kind of an obvious thing to do. A bunch of companies have done this. 10 years ago, there was a company called Second Sight that got all the way to market with an epiretinol stimulator. But when they did this, they were just able to get these flashes of light. And I think kind of like with pharma, because these When you're stuck in these technological local minima, you can rationalize a lot of things. And so there's a whole culture out there that thinks that more phosphenes is vision.
And if I just get more flashes of light, then eventually these are kind of like pixels and I'm going to get vision. And neurologically, it doesn't work this way because you don't see the image on the eye. You experience the world model and really have to update the world model. And the phosphenes are not updating the world model in the way that you need. But there really aren't any subretinal implants out there. There's one other device and so just the placement of this under the retina like if you go and ask a vit ret surgeon who is especially it does this a lot of they're gonna be like this is really tricky like I don't know how to do that you're gonna cause retinal attachments like this is not true like it actually is not that hard and totally fine but that in itself was like somewhat contrarian and then it was an empirical discovery that if you stimulate the bipolar cells you get you get vision and So when we think about competing in this, can other people see that and make a subretinal implant?
Sure. But the real trick in Prima is the fact that it's powered photovoltaically. So let me explain a little bit about this device. It's a tiny little chip. Scope, you see all these little cells. Each one of those is essentially a solar panel. So when we place this under the retina, there's no cable coming out of the eye. There's no battery. It's just this little chip. And so the second sight device, this was a four and a half hour surgery with a belt around the eyeball with a titanium box on the side with a power coil and a bunch of electronics. We don't have any of that because the chip with the photovoltaic array is powered by glasses that project an infrared laser.
And wherever that laser falls on the implant, it stimulates it. and so we're by powering it photovoltaically we're able to have this device that solves a lot of the historical problems and this is the area where we have a lot of deep IP and so there's like a lot of different tricks that I think come from having you have to start from this first principles understanding of like what is the anatomy that we're dealing with and like what is the goal here and what is the full toolbox of of modern technology available for this and It's taking things like, oh, this looks like an image sensor. We know how to make image sensors.
Everybody in this room has a multi-megapixel image sensor in their pocket. This is really easy now. And if you take that same technology and use it a different way, then you can put it together for this.
Speaker 3
Okay, I promise. This side, maybe, do you want to just pass the mic there? Yeah, there we go. So fascinating I'm curious just to like a little bit of the future I would assume the goal is to have like a one-to-one connection between these electrodes and
Speaker 4
neurons at some point and so I'm curious A, do you think that's possible or is there some sort of you know second law thermodynamics that's stopping that from happening and if it is possible is the goal at some point to have coverage of all the inputs and outputs like are we gonna do that you know in 2050 beyond vision yeah so okay so two
Speaker 2
different parts of this so the first is there as you scale up So the implant's small and it doesn't cover the full area of atrophy, much less the full retina. Obviously the eye is curved. It's tough to make chips that are that curved. So now you start thinking about multiple different chiplets. As you have a larger surface area under the retina, you do risk a retinal detachment. You don't want the retina to come off the back of the eye. And so there are ways to deal with that. This is ongoing research. But there's, again, at science we have a broad mandate to to look at how to solve these problems.
Like, we weren't founded around a single asset. Like, the Primo was an acquisition. Now, we knew what we were looking for, and I think we were very prepared for that, but that was where, like, this is the best thing that works now. The electrical simulator, there's, like, a four-by-four grid of, like, these two cell layers, or, like, there's a gene therapy way to do it, there's an electrical way to do it. We kind of mapped out the full space of possibilities here. And we want to provide the best product for restoring vision to the blind. Now, I think that that soon will be Prima. In 10 years, it could be Prima 6.
It could also be a gene therapy. We have another vision program that uses A gene therapy that makes those cells light sensitive themselves. So instead of having a chip under the eye that can stimulate them with light, what if we could express a protein in the bipolar cells that basically puts the stimulating pixel in each of the cells? And so that would be how you get to kind of every cell you can communicate with. To do that, you need to solve some hard problems. You have to solve some hard problems in that protein design, which I think our group in in ops engineering is the best in the world and has been able to make real advances in that, but has to go through the whole clinical trial process.
Now to the other half of your question about all of the other senses. I mean, so we've had cochlear implants for decades. We have had we're getting motor decoders. We There's interesting research going on in providing sensation back to the brain secondary to motor control. But I think that if you can provide vision, hearing, balance, a kilobit per second of motor control, then really you're halfway to something really cool. And I think the big missing piece there is the visual prosthesis that have that now. And so I think that, again, this stuff is coming on less than a decade timescale.
Speaker 3
I think just for efficiency's sake, yeah, let's go later.
Speaker 4
Lucky. Thank you both for the fascinating talk. So going a bit speculative. How would you envision do we go from human to superhuman? As in how much are we limited by the bandwidth of the optical nerve? Is the strategy that you mentioned before of having a field of vision that is centered around something and like less in smaller definition at the edges, is that already optimal for the bandwidth that our brain can handle? Or could we just plug in a High Definition Camera to the eye and the eye would and we would have somehow a different perception of reality yeah I mean this is I so the these bottlenecks are co-evolved throughout the brain I think like some people think like oh if I just if I have a BCI then I'll be able to communicate I'll be able to speak so much faster I'll be able to like talk to like have an AI that that's really fast this is I don't that doesn't align with my understanding of of the neuroscience here I think
Speaker 2
like Writing or like language really is thinking and the visual input to the brain again is not a camera It's about updating this world model with these sparse samples and the brains like very efficient at this and so the Now with that said that doesn't mean that some really cool things might not be possible It's You have a finite visual field like you can't see behind you is it possible to to through a BCI just give you more visual field the like that is somewhat more speculative that nobody's ever done that but there's some really intriguing neuroscience that suggests that it might be possible and so that that's a little bit further away but I think we'll see where we at a talk together like a salon and
Speaker 3
people were talking about merging brains from different species Maybe? Well, we were out near Stanford. Yeah.
Speaker 2
Okay. I mean, so all communication is about creating correlations between brains. So when I have a thought, I can serialize this to language, or the language is directly related to the thought, I can send this over vibrations to the air, you see it, you unpack it, and then that lights up a concept space in your brain that corresponds to the idea. that depends on us already sharing these concept spaces. You get these like when you learn a language or when you learn math in school. And if you don't have that, like if you haven't taken calculus, then trying to communicate the idea will be lost here.
You'll have to do it through metaphor. You'll have to find some other way to map it. One of the really interesting things that has come out of AI over the last year or two is this this empirical finding that when you look inside these big AI models the mathematical objects that you see look a lot like the And so that was one of the first clues to me that the AI people were really on the right track. And this idea that these things are stochastic parrots is just totally wrong. And so you can get this clearer sense of what these concept spaces are, how they're developed, how they're implemented both in deep learning models as well as in nature through biology.
And so when you look at different species, obviously we don't share languages, but you can still ask, well, what are the shared semantic spaces and how might you be able to map these? and I think there's been a little bit of work done on this and like interpreting like whale song and birds and some of this is very stereotyped summit in some cases there's things that look more like grammar but underneath you can still you can think about like what are the semantic representations and how can I how can we map these and I think that there is going to be a lot to that how are you doing a couple more sure you okay you guys okay all right I promised this person over here
Speaker 3
yeah
Speaker 4
Much love, Ashlee. Thank you. Yeah, I'll keep this quick. So every agent, whether it's an LLM or a human being or a cat or a mouse, has a privileged ontology. The only reason language works, as you and the other thing you were saying is because we have shared manifolds developed over billions of years. Those manifolds were sampled over many, many iterations of evolution. So my question to you is more about future life, artificial life. Let's suppose that I can 3D print not just any brain. Design it at the cellular level with such resolution that I can choose to create four lobes instead of two lobe brains. I can choose to put the ventral and the occipital pathways and the basal ganglia somewhere else, maybe closer to some other semantic cluster in the brain. Now we're talking about enhanced or different cognition, different forms of human life that didn't exist before. How much of your current process of, like, Brain Mapping and so on would stay and how much of that would have to change?
Speaker 3
Now we're getting somewhere. The last question has to top that. I don't think that again like we're learning a lot about engineering brains biological and synthetic I think like the basic principles are kind of the same and like many things like to your question can you have a brain with four hemispheres like nature has done this there's a pair of conjoined twins in Canada that are one head with four hemispheres inside and it's joined and like really in interesting
Speaker 2
ways and they When they were children, there was various imaging that was done, and they tried to tease apart what did they feel, what elements of their conscious experience did they share. It's impossible for us to imagine, but that doesn't mean it's unphysical. This is not the type of stuff that we do in practice. Give me 10 years, we will be doing it. But yeah, I think that the principles are the same.
Speaker 4
Yeah, I think one of the, there's one failure mode, which is new ontologies that don't exist in human language, but exist in a human biology we created artificially. That's a hard problem to solve.
Speaker 3
Okay. Okay, one last one. Who's going to take us to sci-fi land? Yeah. Here, oh, can we pass the light? Is it still over there? Yeah, okay. Thank you, guys. Also, there's hats at the back.
Speaker 1
I still see. Can you hear me? This is going to be a fun one, light one. So you said earlier, I'm curious, what we see is not reality, but a world model interpretation of reality, et cetera. And so I'm wondering, is this something we know? Is this something you think specifically Do we know that there's a discrete boundary between perception and interpretation? Because if there is, and I don't know about this, I haven't come across that, but if there is, then it would be pretty easy to boost activations or something and then build a night vision app for your stuff, or Beautify app for your implants. And that would be a great product, a little fun too.
Speaker 2
Well, I mean, so like night vision, we already have. Like you can put on goggles, right? Like we use night vision all the time. That embeds into regular vision. Like the question of could you develop, could you engineer a totally novel, phenomenal mode with a different structure, something like a vector sense, something that we really don't have? Yes. Yeah, I mean, probably. Evolution has done a pretty good job of spanning the information available They run on the same hardware so we don't know the boundary between what I perceive and what I understand I'm asking you if you know that there is such a boundary and if so can
Speaker 1
we tap into it and add a filter because that would be a great product
Speaker 2
Well, I mean, so in a basic sense, like this has to be true, right? Like the brain is encased in the skull, is not magically or telepathically connected to the world. Like when you see the wall, like the room out there, what you're actually experiencing is neural activity and all the brain ever gets are electrical pulses down a small number of cables, the spinal and cranial nerves. And so in some sense, the electrical activity in the spinal and cranial nerves is that totally defines your connection to reality. And all of any of your experience is neural activity. And so if you can alter the brain, you alter your effective reality, like in a trivial sense,
Speaker 3
right? OK. Okay. I'm going to ask one last question. Thank you all so much for coming. Thank you, Max, for doing this. I always feel like you always end up as a philosopher in all these discussions, and I appreciate that you're able to go there so eloquently. It's kind of like why I love talking to you. It's so thought-provoking. So maybe this question is, I don't know if it's too easy or cheap. I'm just always trying to Get how you picture the world. I'm going to pick 20 years, but you can kind of like I can't see 20 years anymore. But well, OK, so pick pick whatever number you want and whether it's whether it's sort of AI or more biotech you pick. Just try it like in your head. you know what what do you if it's roughly 20 years like what do you think would just be the most surprising thing happening in the world at that time yeah I mean I've got this like event horizon in my mind at about 2035 now I mean I think that
Speaker 2
the transition like AI is real like I think that like that is not going back in the bottle. It's not hitting a wall. And I think there's going to be many things like BCI is independent from that. But we're going through another industrial revolution like there's for thousands of years. We're living in a society that did not have a concept of progress. Like if you were medieval peasant, there was no sense like, oh, there's going to be new products soon that are going to be better. It was just like it was static. And that was that was a deeply ingrained in the perception of reality. and now we have a sense of progress because like you might have seen like the graph of if you just Google like GDP over the long run the graph of productivity it's like flat for thousands of years and then in the mid-1800s it does this and I think that there's this idea sometimes that this is recent like oh they started in the 90s or they started in 2000s and it's been accelerating since then like no this started in the mid-1800s and it's been accelerating since but there was a generation that went from like Looms in the living room making textiles to working in factories in the city and in the near and over a short term like their lives got worse like it was not fun to go through the Industrial Revolution and this led to things like the labor movement and led to environmental and a lot of the modern regulatory environment came from the experience of like acutely people's lives like got worse and bad things happen and we learned from that and then we learned to thrive in that new world and we and then after that there was a generation that went from like not having a horse or like riding a horse and buggy to seeing a man land on the moon that was like roughly a lifespan and we're gonna Over the next 20 years the transition is of that scale and I think it's important to remember like this has happened before this has happened several times before and and it's just like I don't like you I don't think there's anything you could have said to somebody in in 1900 like before relativity before cars before jet aircraft that would have helped them understand what their retirement was going to look like
Speaker 3
Yeah, okay. Okay, well, I hope you guys have enjoyed this. I enjoyed it. Thank you, Mac, so much. And like a really heartfelt thank you. When I saw the invite list and I look at like our subscribers and who's reading our stories and everything, I saw so many familiar names, even though I feel like I know some of you. And so, you know, Core Memory has been at this for a bit over a year. So thank you all so much for showing up, for reading and watching. Everything we make and coming out to meet us in person. I don't think we get kicked out of here. I think there's some more food and drinks. And so if you guys want to continue the discussion, please do. And just thank you. The Core Memory Podcast is hosted by me, Ashley Vance, and or Kylie Robison, or both of us together. It is produced by me and David Mickelson, Our theme song is by James Mercer and John Sortland and the show is edited always by the John Sortland. Thank you so much to Brex and Send Cut Send for all your support and thank you most of all to everybody for listening or watching. We love you. Please leave us a like, a review, a subscribe, all those tremendous things. Thank you and we'll see you again.